about
Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessmentImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsCurrent methods for detecting antibodies against erythropoietin and other recombinant proteins.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.Recombinant erythropoietin in clinical practice.Resistance of dialyzed patients to erythropoietin.Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectRecommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia.A Systematic Analysis of the Structures of Heterologously Expressed Proteins and Those from Their Native Hosts in the RCSB PDB Archive.Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.Erythropoietin-induced, antibody-mediated pure red cell aplasia.Epoetin-associated pure red cell aplasia: past, present, and future considerationsClinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation.Scientific considerations for assessing biosimilar products.
P2860
Q24675466-E4A19F48-8D03-4700-881D-3265563EB310Q26738810-3F9C6648-67A5-4643-826F-EEFD368F6957Q33593537-EBFBE73B-F704-406C-9E73-943B9F23F2A8Q33784812-BE7EF86A-3A4F-4DD6-9C2C-33D1E6B527D5Q34629805-1E5F4FC3-45B8-48BA-B124-90DE9F351D0AQ35190989-60A3A7EA-073A-4BD5-A74D-F6C7A3EF90ECQ35694046-F4C3C0D4-5C54-4DC6-9F0D-C97AC5355D9BQ35847694-5B0B87B9-8F3D-4607-92A9-722A08BFD2B3Q35937154-0FDD1786-0FBB-47FC-B764-6C0231484524Q36102601-BCEE134C-1A12-4503-94CD-9F472FFC0A03Q36194596-03B6D0CE-E75F-4D84-B022-FEDB9C62C356Q36310926-5B479831-CCB2-4EC2-B0F2-F6398EE06D7EQ37164738-078A793D-2711-4CCE-8062-0455E6F19799Q37700537-D6BCDB44-E058-47B7-A410-E3546BC99B91Q41944133-A3412D6D-987A-4B4E-97DB-A95E7DB0B3FBQ44770928-3B6818A7-CAB8-4A92-A67E-BAA134A97469Q50429210-E53C5B33-085C-4D44-AC44-7AF667BEF886
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Antibodies against rHuEPO: native and recombinant.
@en
Antibodies against rHuEPO: native and recombinant.
@nl
type
label
Antibodies against rHuEPO: native and recombinant.
@en
Antibodies against rHuEPO: native and recombinant.
@nl
prefLabel
Antibodies against rHuEPO: native and recombinant.
@en
Antibodies against rHuEPO: native and recombinant.
@nl
P356
P1476
Antibodies against rHuEPO: native and recombinant.
@en
P2093
Nicole Casadevall
P356
10.1093/NDT/17.SUPPL_5.42
P407
P478
17 Suppl 5
P577
2002-01-01T00:00:00Z